Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
D. Hui, A. Mahayiddin, C. Roa, K. H. Kwa, D. Bredenbröker, U. M. Goehring, H. P. Kuo, S. D. Lee (Shatin, Hong Kong; Kuala Lumpur, Malaysia; Manila, Philippines; Konstanz, Germany; Taipei, Taiwan; Seoul, Republic Of Korea). Roflumilast in Asian patients with COPD: A randomised placebo-controlled trial. Eur Respir J 2011; 38: Suppl. 55, 3364

Member's Comments

No comment yet.

Related content which might interest you: Umeclidinium in patients with COPD: a randomised, placebo-controlled study Source: Eur Respir J 2014; 43: 72-81 Year: 2004 Randomised, double-blind, placebo-controlled trial of EPS® 7630 in adults with COPD Source: Annual Congress 2009 - Healthcare and treatment of COPD Year: 2009 Azithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19: a randomised double-blinded placebo-controlled trial Source: Eur Respir J, 59 (1) 2100752; 10.1183/13993003.00752-2021 Year: 2022 A randomised, placebo-controlled trial of inhaled mannitol in patients with bronchiectasis Source: Annual Congress 2008 - Infectious lung diseases including tuberculosis Year: 2008 Azithromycin for treatment of hospitalised COVID-19 patients: a randomised, multicentre, open-label clinical trial (DAWn-AZITHRO) Source: ERJ Open Res, 8 (1) 00610-2021; 10.1183/23120541.00610-2021 Year: 2022 Antibiotic in non-purulent hospitalised-treated exacerbations of COPD: a randomised double-blind placebo-controlled trial Source: International Congress 2019 – Airway infection in COPD Year: 2019 Working memory training efficacy in COPD: the randomised, double-blind, placebo-controlled Cogtrain trial Source: ERJ Open Res, 7 (4) 00475-2021; 10.1183/23120541.00475-2021 Year: 2021 PRAISE, a randomized, placebo-controlled, double-blind Phase 2 clinical trial of pamrevlumab (FG-3019) in IPF patients Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): treatment highlights Year: 2017 RCT Abstract - Randomized, double-blind, placebo-controlled, phase III clinical trial with MV130, a sublingual bacterial immunotherapy to prevent COPD exacerbations Source: Virtual Congress 2021 – ALERT: COPD Year: 2021 Tiotropium treatment for bronchiectasis (ROBUST): a randomized, placebo-controlled, crossover trial Source: International Congress 2017 – Bronchodilators and bronchoprotectors Year: 2017 A randomised controlled trial of zafirlukast in acute asthma Source: Eur Respir J 2005; 26: Suppl. 49, 254s Year: 2005 Methotrexate in treatment of severe difficult-to-treat asthma: randomized, double-blind, placebo-controlled study Source: Annual Congress 2007 - Towards controlling severe asthma Year: 2007 ß-blockers in exacerbations of COPD: feasibility of a randomised controlled trial Source: ERJ Open Res, 3 (1) 00090-2016; 10.1183/23120541.00090-2016 Year: 2017 Can simvastatin reduce COPD exacerbations? A randomised double-blind controlled study Source: Eur Respir J, 58 (1) 2001798; 10.1183/13993003.01798-2020 Year: 2021 Pulmonary vasodilator therapy in severe COPD: a double-blind, placebo-controlled trial Source: Eur Respir J 2007; 30: Suppl. 51, 525s Year: 2007 Azithromycin and Hydroxychloroquine in hospitalized patients with confirmed SARS-CoV-2 infection - a randomized placebo-controlled trial (ProPAC-COVID Trial) Source: Virtual Congress 2021 – COVID - 19 treatments Year: 2021 A prospective randomised double-blind placebo controlled trial of venlafaxine in patients with stable chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2006; 28: Suppl. 50, 32s Year: 2006 Cardiac impact of inhaled therapy in the largest randomised placebo-controlled trial in COPD history: have we reached the SUMMIT? Source: ERJ Open Res 2016: 00055-2016 Year: 2016 A randomised, open-label study of umeclidinium versus glycopyrronium in patients with COPD Source: ERJ Open Res 2016: 00101-2015 Year: 2016